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FIGURE 1 Alirocumab Restores Maximal LDLR Cell Surface Expression Levels in Non-
FH, HeFH and Receptor Defective HoFH
Control ﬁbroblasts (A), heterozygous familial hypercholesterolemia (HeFH) ﬁbroblasts
(B), receptor-defective HoFH ﬁbroblasts (C), and receptor-negative homozygous
familial hypercholesterolemia (HoFH) ﬁbroblasts (D) were grown in 20% FCS
or 0.5% FCS with increasing concentrations of mevastatin for 24 h. Fibroblasts
grown in 0.5% FCS and 40 mg/ml of mevastatin were subsequently treated with
increasing doses of wild-type rPCSK9 (0 to 6,000 ng/ml) or rPCSK9-D374Y
(0 to 600 ng/ml) for 4 h with or without increasing doses of alirocumab (0 to
19,200 ng/ml). LDLR cell surface expression was assessed by ﬂow cytometry
(3). *p < 0.01 versus 0.5% FCS. **p < 0.001 versus 0.5% FCSþ 40 mg/ml
mevastatin. ***p < 0.01 versus 0.5% FCSþ 40 mg/ml mevastatin þ 6,000 ng/ml
rPCSK9 wild type/600 ng/ml rPCSK9-D374Y. Histograms represent the mean 
SEM of at least 4 independent experiments. Representative ﬂuorescence charts
are displayed. FCS ¼ fetal calf serum; FH ¼ familial hypercholesterolemia;
LDLR ¼ low-density lipoprotein receptor; PCSK9 ¼ proprotein convertase subtilisin
kexin type 9.
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Cardiovascular Crisis
Glove UpI read with great interest the editorial by Fuster
(1), detailing both expanded recommendations to
address the global burden of cardiovascular disease
and the necessity for evaluating implemented
recommendations by measuring outcomes. These are
important steps to address a crisis unappreciated by
the majority of U.S.-based cardiologists. However,
the American College of Cardiology (ACC) and its
members can do more to address current needs.
Cardiovascular disease in the developing world is as
much a disease of poverty as newfound afﬂuence.
Carbohydrates are cheap and available. Local agricul-
ture is more climate dependent than in the United
States and the cost of modern farming practices limits
production. Knowledge of a heart healthy diet and the
acquisition of that diet are wholly separate. Epi-
demiologic assessments and disease prevention
incompletely addresses existing clinical needs. The
treatment of disease at the local level could be
augmented by cardiologists from the developed world
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will never be enough local physicians to provide these
services due to both emigration and the overwhelming
state of third world general medical care. Groups such
as doc2doc and Pacemaker International are but 2 ex-
amples of small groups making a difference.
The ACC can be a source for regions or commu-
nities seeking advanced cardiovascular care. It can
identify members with an interest in providing
volunteer services in a tangible, sustainable, and local
manner. An ACC committee on International Volun-
teer Cardiology comprising physicians with volunteer
experience might address feasibility concerns and
individualize a response team based on local needs
and available members. Can services such as pace-
maker insertion, peripheral revascularization for limb
salvage, and even low-risk coronary or valve inter-
vention be offered without full service cardiovascular
surgery at acceptable risk by experts in their ﬁeld?
Can telemedicine create a virtual hospital with a team
that is known to local physicians from previous mis-
sions expediting referrals and optimize the time on
the ground by visiting cardiologists? Perhaps a forum
at the annual meeting focusing on these issues to
chronicle the successes and failures of those involved
in provision of volunteer cardiology to the under-
privileged and disadvantaged could provide insights.
This should highlight not how to do more with more
but how to do something with very little.
Confronting the global cardiovascular crisis requi-
res more than education. It requires what cardiolo-
gists do best. Rolling up our sleeves and getting our
hands dirty.*Mark Lanzieri, MD
*Central Maine Heart Association
60 High Street
Lewiston, Maine 04240
E-mail: marklanzieri73@hotmail.com
http://dx.doi.org/10.1016/j.jacc.2014.09.027
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This electrocardiography (ECG) tracing obtained during a gated
cardiac computed tomography (CT) scan demonstrates asystole
occurring soon after the scan begins in a pacemaker-dependentEffect of Computed
Tomography Imaging
on Rhythm Devices in
Real-World Practicepatient (top row of tracing). Once the CT beam passed the
pacemaker generator, the rhythm returned to ventricular pacing
(second row of tracing).We read with interest the article by Hussein et al. (1).
The publication focused on non-cardiovascular (andtherefore non-ECG-gated) studies. Although we
agree with the authors’ conclusions supporting the
clinical safety of computed tomography (CT) scans
in patients with these devices, we have observed
several cases of CT-induced arrhythmia during
gated cardiac examinations in patients with rhythm
management devices. The resultant arrhythmias
rendered the examinations non-diagnostic, thus
exposing patients to unnecessary radiation.
Our observed cases involved apparent ventricular
oversensing, which led to pacemaker suppression,
causing brief periods of ventricular asystole (Figure 1).
These occurred while the CT beam was directly
in line with the pacemaker generator. As suggested
by Hussein et al. (and others) (2,3) the effects were
transient, lasting <4 s. Consistent with the authors’
ﬁndings, none of our cases led to clinically signiﬁcant
adverse events. CT interference was detected because
these studies were electrocardiography (ECG)-gated,
and demonstrated temporary pacemaker suppression
on recorded ECG strips. More importantly, evaluation
of ventricular function, the primary reason for the
examinations, was precluded by the resultant
temporary cessation of the cardiac cycle, which was
imaged as a nonmoving heart.
These cases are important for several reasons.
First, they conﬁrm the prior reports cited by the
authors that CT beams do indeed transiently inter-
fere with pacemaker function, leading to ventricular
oversensing during routine clinical scans. This
interference, however, is transient and unlikely
